{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:44:35Z","timestamp":1785894275768,"version":"3.56.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009414","name":"Istituto Oncologico Veneto IRCCS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cllc.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:01:16Z","timestamp":1779897676000},"page":"31-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma"],"prefix":"10.1016","volume":"27","author":[{"given":"Giulia","family":"Pasello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Scattolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Faccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Marulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Luca","family":"Ceresoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bearz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana Letizia","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Callegarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Del Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"De Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pezzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dell\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2026.05.004_bib0001","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-025-00640-3","article-title":"Pleural mesothelioma","volume":"11","author":"Fennell","year":"2025","journal-title":"Nat Rev Dis Prim"},{"issue":"5","key":"10.1016\/j.cllc.2026.05.004_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-024-05802-6","article-title":"Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990\u20132019","volume":"150","author":"Chen","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.05.004_bib0003","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.cllc.2026.05.004_bib0004","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of Pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10272","key":"10.1016\/j.cllc.2026.05.004_bib0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"10419","key":"10.1016\/j.cllc.2026.05.004_bib0006","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.05.004_bib0007","doi-asserted-by":"crossref","unstructured":"Nowak A, Forde P, Brown C, et al. LBA104 Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma: A phase III randomised trial. Annals of Oncology, 36S1646. ESMO Congr; 2025.","DOI":"10.1016\/j.annonc.2025.09.121"},{"issue":"8","key":"10.1016\/j.cllc.2026.05.004_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02425","article-title":"Treatment of pleural mesothelioma: ASCO guideline update","volume":"43","author":"Kindler","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.05.004_bib0009","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"Lung cancer a systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2026.05.004_bib0010","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"Taioli","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cllc.2026.05.004_bib0011","doi-asserted-by":"crossref","unstructured":"Schil PE Van, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. 2010;36(6):1362-1369. doi:10.1183\/09031936.00039510","DOI":"10.1183\/09031936.00039510"},{"key":"10.1016\/j.cllc.2026.05.004_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.critrevonc.2016.05.004","article-title":"The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: state of the art and recommendations","volume":"104","author":"Novello","year":"2016","journal-title":"Crit Rev Oncol \/Hematol"},{"key":"10.1016\/j.cllc.2026.05.004_bib0013","doi-asserted-by":"crossref","unstructured":"Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. 2009;27(18):3007-3013. doi:10.1200\/JCO.2008.20.3943","DOI":"10.1200\/JCO.2008.20.3943"},{"issue":"3","key":"10.1016\/j.cllc.2026.05.004_bib0014","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.athoracsur.2019.03.052","article-title":"Disparities in compliance with national guidelines for the treatment of malignant pleural mesothelioma","volume":"108","author":"Espinoza-mercado","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cllc.2026.05.004_bib0015","doi-asserted-by":"crossref","unstructured":"Lee H, Jang H, Ramineni M, et al. A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma. 2024;29(3):548-559. doi:10.1158\/1078-0432.CCR-22-2566.A","DOI":"10.1158\/1078-0432.CCR-22-2566"},{"key":"10.1016\/j.cllc.2026.05.004_bib0016","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.05.004_bib0017","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cllc.2026.05.004_bib0018","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir"},{"issue":"6","key":"10.1016\/j.cllc.2026.05.004_bib0019","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S2213-2600(24)00146-2","article-title":"MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma","volume":"12","author":"Grosso","year":"2024","journal-title":"Lancet Respir"},{"issue":"June","key":"10.1016\/j.cllc.2026.05.004_bib0020","article-title":"Towards a new approach in pleural mesothelioma : perioperative immunotherapy and its implications","volume":"215","author":"Ambrosini","year":"2025","journal-title":"Crit Rev Oncol \/Hematol"},{"key":"10.1016\/j.cllc.2026.05.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03958-3","article-title":"Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses","author":"Reuss","year":"2025","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.cllc.2026.05.004_bib22","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2024.42.16_suppl.8003","article-title":"Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study","volume":"42","author":"Offin","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:48:32Z","timestamp":1785890912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1525730426000720"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.05.004","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}